ZYNLONTA DLBCL
-
Three Cancer Drug Programs Advanced This Week and Nobody Noticed
MAIA Biotechnology got FDA clearance to open US enrollment for its Phase 2 lung cancer trial on June 3. ADC Therapeutics released Phase 3 data confirming ZYNLONTA extends progression-free survival in lymphoma the same day. Verastem got an FDA Fast Track for its KRAS G12D inhibitor in lung cancer the day after. Three different companies,…
